| Literature DB >> 23552602 |
M Michaelis1, S Barth, R Breitling, J Bruch, D Steinberger, F Rothweiler, K Hackmann, E Schröck, H W Doerr, D K Griffin, J Cinatl, J Cinatl.
Abstract
The human cytomegalovirus (HCMV) is suspected to increase tumour malignancy by infection of cancer and/or stroma cells (oncomodulation). So far, oncomodulatory mechanisms have been attributed to the presence of HCMV and direct action of its gene products on cancer cells. Here, we investigated whether the prolonged presence of HCMV can result in the irreversible selection of a cancer cell population with increased malignancy. The neuroblastoma cell line UKF-NB-4 was long-term (200 passages) infected with the HCMV strain Hi91 (UKF-NB-4(Hi)) before virus eradication using ganciclovir (UKF-NB-4(HiGCV)). Global gene expression profiling of UKF-NB-4, UKF-NB-4(Hi) and UKF-NB-4(HiGCV) cells and subsequent bioinformatic signal transduction pathway analysis revealed clear differences between UKF-NB-4 and UKF-NB-4(Hi), as well as between UKF-NB-4 and UKF-NB-4(HiGCV) cells, but only minor differences between UKF-NB-4(Hi) and UKF-NB-4(HiGCV) cells. Investigation of the expression of a subset of five genes in different chronically HCMV-infected cell lines before and after virus eradication suggested that long-term HCMV infection reproducibly causes specific changes. Array comparative genomic hybridisation showed virtually the same genomic differences for the comparisons UKF-NB-4(Hi)/UKF-NB-4 and UKF-NB-4(HiGCV)/UKF-NB-4. UKF-NB-4(Hi) cells are characterised by an increased invasive potential compared with UKF-NB-4 cells. This phenotype was completely retained in UKF-NB-4(HiGCV) cells. Moreover, there was a substantial overlap in the signal transduction pathways that differed significantly between UKF-NB-4(Hi)/UKF-NB-4(HiGCV) and UKF-NB-4 cells and those differentially regulated between tumour tissues from neuroblastoma patients with favourable or poor outcome. In conclusion, we present the first experimental evidence that long-term HCMV infection can result in the selection of tumour cell populations with enhanced malignancy.Entities:
Year: 2012 PMID: 23552602 PMCID: PMC3412641 DOI: 10.1038/oncsis.2012.10
Source DB: PubMed Journal: Oncogenesis ISSN: 2157-9024 Impact factor: 7.485
Figure 1Establishment of UKF-NB-4Hi and UKF-NB-4HiGCV cells. UKF-NB-4 cells were infected once with HCMV strain Hi at MOI 10 and then subcultured without further addition of virus (UKF-NB-4Hi). After 200 passages, UKF-NB-4Hi cells were treated for six passages with 20 μM ganciclovir (GCV) until no HCMV IEA or late antigen (LA) expression were detectable anymore. (a) Representative pictures showing immunostaining of UKF-NB-4, UKF-NB-4Hi or UKF-NB-4HiGCV cells for IEA or LA. (b) Fraction of HCMV antigen-expressing cells in UKF-NB-4Hi cells at different passages after initial infection. (c) HCMV antigen expression in GCV-treated UKF-NB-4Hi cells at different passages in comparison with non-treated UKF-NB-4Hi cells. Values represent mean±s.d. from three independent experiments. *P<0.05 relative to non-treated UKF-NB-4Hi cells. (d) HCMV antigen expression in GCV-cured UKF-NB-4Hi (UKF-NB-4HiGCV) cells after cultivation for 10 passages in the absence of GCV in comparison with non-treated UKF-NB-4Hi cells. n.d., not detectable.
Figure 2Comparison of global gene expression in UKF-NB-4, UKF-NB-4Hi and UKF-NB-4HiGCV cells by gene microarray. (a) Hierarchical cluster analysis based on the Pearson correlation coefficient. (b) Numbers of genes significantly differentially expressed (FDR<0.05) between the investigated cell lines.
Signal transduction pathways that are significantly differentially regulated (P<0.05, corrected for multiple testing) in UKF-NB-4Hi vs UKF-NB-4 and UKF-NB-4HiGCV vs UKF-NB-4 cells as identified by PANTHER pathway analysis
| Wnt signalling (348) | 1 | 1 |
| Ras pathway (91) | 2 | 3 |
| Ubiquitin proteasome pathway (89) | 3 | 4 |
| Cadherin signalling pathway (168) | 4 | 2 |
| Parkinson disease (106) | 5 | 5 |
| Angiogenesis (229) | 6 | 12 |
| Integrin signalling pathway (227) | 7 | 9 |
| EGF receptor signalling pathway (150) | 8 | 6 |
| PDGF signalling pathway (187) | 9 | 11 |
| p53 pathway (136) | 11 | 7 |
| Huntington disease (172) | 12 | 8 |
| p53 pathways feedback loops 2 (66) | 13 | 13 |
| Cytoskeletal regulation by Rho GTPase (111) | 16 | 16 |
Abbreviations: EGF, epidermal growth factor; PDGF, platelet-derived growth factor.
Pathways were ranked by their P-values with the lowest P-value being rank 1.
Pathway genes differentially expressed between the data sets (FDR<0.05). In total, 25 431 genes were annotated in the PANTHER reference list. 8832 genes were differentially expressed between UKF-NB-4Hi and UKF-NB-4, 8873 between UKF-NB-4HiGCV and UKF-NB-4.
Figure 3Array CGH of all 24 human chromosomes resulting from comparisons of UKF-NB-4Hi cells (upper plot) and UKF-NB-4HiGCV cells (bottom plot), both compared with UKF-NB-4 cells. Results suggest that both UKF-NB-4Hi and UKF-NB-4HiGCV have very similar karyotypes: whole-chromosome gain and loss (e.g., on chromosomes 6 and 18), losses and gains of chromosome segments, e.g., terminal 2p and 12q, as well as amplification and loss on individual loci.
Figure 4Adhesion of UKF-NB-4, UKF-NB-4Hi and UKF-NB-4HiGCV cells to endothelial cell monolayers, transmigration and endothelial cell monolayer distruction. (a) Fractions of cells that adhered to HUVEC monolayers (in the presence or absence of an α5β1-blocking antibody (a, b)) were expressed as the percentage of the total number of input cells. (b) Fractions of cells that transmigrated through HUVEC monolayers (in the presence or absence of an α5β1-blocking antibody (a, b)) were expressed as the percentage of the total number of adherent cells. (c) Focal endothelial cell monolayer disruption (in the presence or absence of an α5β1-blocking antibody (a, b)) was expressed as the percentage of the cell-free area. Values represent mean±s.d. from three independent experiments. *P<0.05 relative to UKF-NB-4; #P<0.05 relative to the corresponding cell line in the absence of α5β1-blocking antibody; n.d., not detectable; AB, antibody.
Analysis of signalling pathways significantly differentially expressed (P<0.05, corrected for multiple testing) between UKF-NB-4Hi and UKF-NB-4HiGCV cells and UKF-NB-4 in data sets of neuroblastoma patients[27, 28] PANTHER pathway analysis
| Pathway | ||
|---|---|---|
| | ||
| Wnt signalling | 14 (2.33 × 10−3) | 1 (4.13 × 10−14) |
| Ras pathway | 4 (6.70 × 10−7) | 14 (1.58 × 10−4) |
| Ubiquitin proteasome pathway | 44 (4.82 × 10−1) | 15 (1.84 × 10−4) |
| Cadherin signalling pathway | 76 (1.00 × 100) | 23 (4.44 × 10−3) |
| Parkinson disease | 9 (2.49 × 10−4) | 27 (1.49 × 10−2) |
| Angiogenesis | 1 (5.60 × 10−13) | 2 (1.31 × 10−9) |
| Integrin signalling pathway | 10 (2.67 × 10−4) | 11 (1.63 × 10−5) |
| EGF receptor signalling pathway | 11 (5.11 × 10−4) | 6 (4.90 × 10−7) |
| PDGF signalling pathway | 3 (4.53 × 10−8) | 4 (2.74 × 10−8) |
| p53 pathway | 5 (5.57 × 10−6) | 8 (8.60 × 10−7) |
| Huntington disease | 42 (4.34 × 10−1) | 3 (2.15 × 10−8) |
| p53 pathways feedback loops 2 | 6 (6.63 × 10−6) | 39 (1.18 × 10−1) |
| Cytoskeletal regulation by Rho GTPase | 86 (1.00 × 100) | 18 (4.98 × 10−4) |
Abbreviations: EGF, epidermal growth factor; PDGF, platelet-derived growth factor.
21 out of 153 pathways were significantly differentially regulated (P<0.05).
32 out of 153 pathways were significantly differentially regulated (P<0.05).
Pathways were ranked according to their P-values for the comparison of non-favourable vs favourable outcome with the lowest P-value being rank 1.